Determination of NK cell immunophenotype and cytokine profile in patients with Rocky Mountain spotted fever

Carolina Maynez-Prieto^{1-2†}, Jaime R. Adame-Gallegos^{1†}, Moisés Ramírez-López³, Estefanía Quintana-Mendías², Blanca E. Estrada-Aguirre², Maribel Baquera-Arteaga³, Diana Manzanera-Ornelas³, Enrique Guevara-Macías³, Gerardo P. Espino-Solís^{2*}

¹Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Chihuahua, México.

²Laboratorio Nacional de Citometría de Flujo, Facultad de Medicina. Universidad Autónoma de Chihuahua, Chihuahua, México.

³Hospital Infantil de Especialidades de Chihuahua, Chihuahua, México.

[†] These authors contributed equally to the paper.

* Correspondence:

Gerardo P. Espino-Solís
gespinos@uach.mx

Keywords: Rickettsiosis; cytokine profiles; Natural killer cells subsets; Rocky Mountain spotted fever; tick-borne diseases; FACS; flow cytometry

Abstract

The intracellular pathogen *Rickettsia rickettsii* causes tick-borne spotted fever (also called Rocky Mountain spotted fever (RMSF) and is increasingly recognized as an emerging cause of febrile illness in Mexico. However, little is known about the early immune responses to infection. Four RMSF pediatric patients on acute phase and eight healthy controls from Chihuahua, Mexico were recruited. The natural killer cell (NK) immunophenotype and the cytokine profile in peripheral blood were characterized by flow cytometry. The population of cytotoxic NK cells expressing NKG2D was significantly decreased in patients on 3rd day of hospitalization compared to the first sampling on admission. Interleukins IL-6, IL-8, and IL-10 levels were significantly increased in patients upon admission compared to controls. This study shows that circulating NK cells are numerically decreased, while cytokines induce a pro-inflammatory process in patients.

1 Introduction

Rocky Mountain spotted fever (RMSF) is a tick-borne disease caused by *Rickettsia rickettsii*, an obligate intracellular pathogen that belongs to α -proteobacteria (1,2). In general, tick-borne diseases have been overlooked as neglected tropical diseases despite their global distribution, although their inclusion in the WHO list has been suggested due to their relevance in Public Health (3). In North America, RMSF is a reemerging infectious disease that primarily affects children living in poverty. In Mexico, in the states of Baja California and Sonora, 2,300 cases and 380 deaths were registered in 2016, and it is estimated that fatality rates are higher in children under 10 years of age (4).

Rickettsia invades endothelial cells promoting their dissemination and causing vasculitis that stimulates cell signaling cascades, which leads to cytokine secretion, initiating infiltration into the vascular cell wall and perivascular space of macrophages, CD8+ T lymphocytes, CD4+ T lymphocytes and NK cells (5). In human in vitro models, endothelial cells increase the expression and secretion of cytokines IL-1 (interleukin-1), IL-6 and TNF α (tumor necrosis factor α); chemokines such as CXCL8 / IL-8 (interleukin-8), CXCL10 / IP-10 (interferon gamma-induced protein 10), CCL2 / MCP-1 (monocyte chemoattractant protein 1), CXCL9 / MIG (interferon gamma-induced monokine) and CCL5 / RANTES that lead to the activation and recruitment of monocytes, NK cells (natural killers) and T lymphocytes to the site of infection leading to the potentiation of the inflammatory response and its elimination (6–10). Monocytes, immature macrophages that circulate in the bloodstream, when infected promote the spread of the pathogen in the vascular endothelium, causing an increase in microvascular permeability leading to rickettsial vasculitis (11–13).

While NK cells, the main population of innate lymphocytes that coordinate early responses to bacterial infections, participate on the regulation of the immune response to rickettsia, particularly by preventing early endothelial injury that results in tissue damage (14,15). In murine models, it is well established that NK cells are involved in early innate defense against rickettsial infection (16,17). However, in humans, the host's early immune responses have not been well characterized. In this study, we investigated serum cytokine and chemokine and NK responses in febrile children with acute *R. rickettsii* infection.

2 Materials and methods

2.1 Study subjects and inclusion criteria

The study group included four patients with rickettsiosis (2 female and 2 males; mean age $\pm$ SD, 5 $\pm$ 5 years) from Children's Hospital of Specialties of the state of Chihuahua and eight healthy controls matched by age and sex (6 female and 6 male; mean age $\pm$ SD, 5 $\pm$ 5 years). Everyone was punctured in the saphenous vein to obtain blood samples that were collected in EDTA anticoagulant tubes. The diagnoses of the patients required the detection of the *gltA* gene of *Rickettsia spp.* by polymerase chain reaction (PCR) using test kits, not having a history of autoimmune, cardiovascular, cerebral and / or osteoarticular disorders; secondary acute infectious processes, and ingestion of medications prior to the first sampling. All healthy controls were recruited from the state of Chihuahua, Mexico, which was the same area where the patients were infected. The controls must not have a history of tick bite prior to sampling; autoimmune, cardiovascular, cerebral and / or osteoarticular disorders; acute infectious processes, and ingestion of drugs prior to sampling.

2.2 Statement of ethics

The study protocol complied with the guidelines established in the Regulations of the General Health Law in matters of health research, the Declaration of Helsinki and the Good Clinical Practices issued by the National Bioethics Commission. It was also approved by the Research Ethics Committee of the Faculty of Medicine and Biomedical Sciences of the Autonomous University of Chihuahua with registration number CI-056-19. All participants or their legal representatives gave their consent to take part in the present study, as well as to have the results of this research work published.

2.3 Cytokine and Chemokine Profiles

Cytokine and chemokine levels was evaluated from sera samples obtained from patients with rickettsiosis and control donors. For this, the BD cytometric bead array (CBA) human inflammation kit (Catalog No. 551811), human Th1/Th2/Th17 kit (Catalog No. 560484) and human chemokine kit (Catalog No. 552990) were used following the manufacturer's instructions. Briefly, reaction was made from a Master mix containing 5 μ L of each antibody for the number of reactions to be done. Diluent solution was added to this mixture so that the volume per reaction was 50 μ L of the Master mix. To this volume, 50 μ L of the test sample and 25 μ L of PE were added. The reaction was incubated for 2 h in the dark. Subsequently, 1 mL of wash buffer was added, and it was centrifuged for 5 min at 200 $\times$ g. Finally, 350 μ L of wash buffer was added and it was read on an Attune NxT cytometer in which 10,000 events were recorded at a flow of 100 μ L/min. Results were analyzed with the FlowJo vX.0.7 program. A graph was generated comparing the size (FWD) with the complexity (SSC) of the spheres. In this way the regions of interest corresponding to the fluorescence of PE bound to the antibody were delimited and the fluorescence intensity corresponding to each cytokine was measured. With these values the concentration of each cytokine was calculated in picograms per milliliter (pg/mL).

2.4 NK cells Immunophenotype

100 μ l whole blood were obtained from each sample and stained with the following monoclonal antibodies and reagents: anti-CD3 conjugated with Super Bright 600 (Clone: OKT3, # 63-0037-42), anti-CD16 conjugated with allophycocyanin-H7 (Clone: 3G8, # 560195), anti-CD56 conjugated with allophycocyanin (Clone: CMSSB, # 17-0567-42), anti-CD57 conjugated with Pacific Blue (Clone: TB01, # 12-0577-42), anti-NKG2D conjugated with Fluorescein Isothiocyanate (Clone: 1D11, # 11-5878-42), and anti-NKG2A conjugated with Brilliant™ Blue 700 (Clone: 131411, No. 747926) (all from Thermo Fisher, Waltham, MA). The samples were incubated in the dark for 15 min, then 2 ml of lysis buffer (BD Solution BD FACS™ 10X concentrated lysate, San Diego, CA) were added and incubated in the dark for 10 min. Subsequently, 2 ml of phosphate-buffered saline (PBS) were added and centrifuged at 1.800 rpm for 5 min to remove supernatant, 2 ml of PBS were added again, and they were centrifuged at 1,800 rpm for 5 min. After removing the supernatant, they were resuspended in 500 μ l of PBS. Finally, the resuspended samples were acquired in the Attune NxT cytometer and analyzed in Flow Jo software where the gates strategy to identify the populations was determined (Supplementary Figure 1) (version 10; BD science, San Diego, CA).

3 Results

Levels of pro-inflammatory cytokines were evaluated (IL-1 β , IL-6, IL-8, IL-10, IL-12p70 and TNF α) in sera from children with rickettsiosis in the acute phase of the disease. It was found a significant increase of IL-6, IL-8 and IL-10 in patients upon admission to hospital compared to controls. No variations were found in the concentrations of IL-1 β , IL-12p70 and TNF α between patients and controls (Figure 1). When determining serum chemokine levels (IP-10, MCP-1, MIG, RANTES and

IL-8), significant increase in IP-10, MCP-1, MIG and IL-8 was found in patients upon admission to hospital compared to controls. Whereas no variation was found in RANTES concentration between patients and controls (**Figure 2**).

Related to cytokines secreted during Th1 / Th2 / Th17 responses (IL-2, IL-4, IL-6, IL-10, IL-17A, IFN- γ and TNF- α), within the Th1 response, a significant increase in IFN- γ was found in patients upon admission to hospital compared to controls. No variation was found for TNF α and IL-2. In the Th2 response, a significant increase in IL-6 and IL-10 was found in patients upon admission to the hospital compared to controls, but not with IL-4, where there was no significant variation. In the Th17 response, there was no significant variation of IL-17A between patients and controls (**Figure 3**).

When evaluating the levels of total NK, cytotoxic NK, effector NK, and NK with expression from CD57 NKG2D, NKG2A, a significant decrease in total NK was found and NK with NKG2D expression in patients at admission compared to controls. Likewise, there was a significant decrease in effector NK in the patients on admission compared to the 3rd day (**Figure 4**).

4 Discussion

In vivo RMSF studies in humans evaluating circulating levels of inflammatory mediators and NK are scarce, probably due to the limited availability of patient samples. In the present pilot study, it was observed that in pediatric patients with RMSF it was characterized by a systemic increase in several pro-inflammatory cytokines such as IL-6 and IL-8. This increase has also been reported in other studies of patients with RMSF (8,18,19) reflecting the activation of monocytes / macrophages and endothelial cells infected by rickettsia, and attraction of T and NK lymphocytes (20,21).

Levels of IL-8, IP-10, MCP-1 and MIG showed a significantly high increase in patients upon admission compared to the controls. These chemokine levels are consistent with those reported in pediatric patients infected with *R. felis* during the acute phase, where IL-8, IP-10, and MCP-1 attract immune cells to infection sites and likely reflect initial host responses to *R. rickettsii* (8). Plasma levels of IL-10, a potent inhibitor of TNF α and IL-6, were found to be significantly increased in patients upon admission to hospital. This result is consistent with previous studies in patients with other rickettsiosis (*R. africae* and *R. conorii*) where a significant increase in IL-10 was observed around day 12 after the onset of symptoms, possibly associated with the prevention of a disproportionate inflammatory response (18,22).

There was a decrease observed in circulating NK cells (CD3⁺CD56⁺) in the pediatric patients in this study, that has also been seen in patients with septic shock (23,24), and sepsis due to Gram positive bacteria such as *Streptococcus pneumoniae* and *Staphylococcus aureus*, and Gram-negative bacteria of the genus *Enterobacteria* and *Neisseria meningitidis*. In these cases, sepsis due to gram-positive bacteria the one that produced a greater decrease in NK cells circulating compared to sepsis due to gram-negative bacteria. This could indicate a persistent activation of NK cells during severe infection by gram-positive bacteria, the elimination of which normally requires highly organized host responses, whereas many gram-negative pathogens, as is the case in this study, could be effectively destroyed by complement and antibodies (25). Furthermore, the observed reduction in the number of NK cells could reflect the activation and displacement of these cells to other tissues (15). Additionally, previous studies in human acute viral infections such as influenza and hepatitis B infection also found a decrease in circulating NK cells, also related to the activation and displacement of these cells to other tissues (26,27). However, other authors have reported an increase in NK cells in severe sepsis due to gram-negative bacteria and acute infection by scrub fever caused by *Orientia tsutsugamushi*, which could be

related to increased hematopoiesis, recruitment and auto-proliferation of NK cells in response to cytokines and microbial stimulation (15,28,29). When analyzing the immunophenotype, a decrease in effector NK cells (CD56^{bright}CD16^{dim}) was observed in the patients on the 3rd day after admission. This was not the case with cytotoxic NK cells (CD56^{dim}CD16^{bright}), showing variation between patients and controls. In turn, there was a significant decrease in the expression of NKG2D of the NK cells in the patients upon admission compared to the 3rd day of their hospitalization. This result could be related to the behavior observed during the infection by *O. tsutsugamushi* where, although no significant differences were observed in the proportion of CD56^{bright} / CD56^{dim} NK cell subsets between patients and controls, they exhibited an activated phenotype with higher expression levels of CD69 (29). Based on this information, possibly the patients in this study are also presenting a high level of CD69 expression due to the decrease in the expression of NKG2D, an activating receptor for NK, which participates in the induction of IFN- γ secretion and the positive regulation of CD69 (30).

This event in turn could be one of the main causes of the significant increase in IFN- γ plasma levels, also described in patients with murine typhus (*R. typhi*) and in a patient with infection by *R. slovaca*. The early response to IFN- γ activates intracellular bactericidal mechanisms to further control the spread of infection (19,21).

In conclusion, the increase in pro-inflammatory cytokines together with the decrease of circulating NKs with NKG2D expression during *R. rickettsii* infection suggest a picture of severe sepsis or septic shock. These data could provide information on the health status of the pediatric patient and given that children represent a particular vulnerable group, it is even more important to be able to make an early diagnosis to treat them properly. However, require additional studies of antibody-dependent cellular cytotoxicity, T and B lymphocytes, to elucidate immune responses during infection by *R. rickettsii*.

5 Conflict of Interest

The authors declare no conflicts of interest.

6 Author Contributions

GPES: Conceptualization, project administration, supervision, data analysis, review and editing of manuscript. CMP and JRAG: conceptualization, data analysis, original draft, review and editing of manuscript. EQM, BEEA: FACS analysis. MRL, MBA, DMO, EGM: sample collection and patient resources. All authors contributed to this article and approved the submitted version.

7 Funding

GPES sincerely acknowledges funding from Consejo Nacional de Ciencia y Tecnología (CONACYT), Ciencia Básica Grant No. A1-S-53789. GPES as part of Laboratorio Nacional de Citometría de Flujo appreciates the support from CONACYT- Apoyos para Acciones de Fortalecimiento, Articulación de Infraestructura y Desarrollo de Proyectos Científicos, Tecnológicos y de Innovación en Laboratorios Nacionales Grant No. 315807. CMP and BEEA are supported from CONACYT, Programa de Becas Nacionales from UACH (Scholarship numbers 755772 and 790272, respectively).

8 Acknowledgments

Special thanks to Dra. Guadalupe Virginia Nevárez-Moorillón for her critical remarks. Authors also acknowledge, families and staff at Children's Hospital of Specialties of the state of Chihuahua. Dr.

201 Gumaro Barrios Gallegos, M.C. Gloria Edith Márquez Leos, Dr. Jorge Alain Carmona Sawatsky, and
202 Dra. Leticia Ruiz González from the Health Department of the state of Chihuahua.

203 9 References

- 204 1. Blanc G, Ngwamidiba M, Ogata H, Fournier PE, Claverie JM, Raoult D. Molecular evolution
205 of Rickettsia surface antigens: Evidence of positive selection. *Mol Biol Evol*.
206 2005;22(10):2073–83.
- 207 2. Dantas Torres F. Rocky Mountain spotted fever. Vol. 7, *Lancet Infectious Diseases*. 2007. p.
208 724–32.
- 209 3. Salje J, Weitzel T, Newton PN, Varghese GM, Day N. Rickettsial infections: A blind spot in
210 our view of neglected tropical diseases. *PLoS Negl Trop Dis* [Internet]. 2021 May 1 [cited
211 2021 Nov 17];15(5):e0009353. Available from:
212 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009353>
- 213 4. Álvarez-Hernández G, Roldán JFG, Milan NSH, Lash RR, Behravesh CB, Paddock CD.
214 Rocky Mountain spotted fever in Mexico: past, present, and future. *Lancet Infect Dis*
215 [Internet]. 2017 Jun 1 [cited 2018 Apr 3];17(6):e189–96. Available from:
216 <http://www.ncbi.nlm.nih.gov/pubmed/28365226>
- 217 5. Sahni A, Fang R, Sahni SK, Walker DH. Pathogenesis of Rickettsial Diseases: Pathogenic and
218 Immune Mechanisms of an Endotheliotropic Infection. *Annu Rev Pathol Mech Dis*. 2019
219 Jan;14(1):127–52.
- 220 6. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions.
221 *Immunol Cell Biol*. 2011;89(2).
- 222 7. Osterloh A. Immune response against rickettsiae: lessons from murine infection models. Vol.
223 206, *Medical Microbiology and Immunology*. 2017. p. 403–17.
- 224 8. Rauch J, Sothmann P, Aldrich C, Hogan B, Owusu-Dabo E, May J, et al. Serum cytokine
225 responses in Rickettsia felis infected febrile children, Ghana. *Med Microbiol Immunol*.
226 2018;207(3–4):243–8.
- 227 9. Rydkina E, Turpin LC, Sahni SK. Rickettsia rickettsii infection of human macrovascular and
228 microvascular endothelial cells reveals activation of both common and cell type-specific host
229 response mechanisms. *Infect Immun*. 2010;78(6):2599–606.
- 230 10. Sahni SK, Rydkina E. Host-cell interactions with pathogenic Rickettsia species. *Future*
231 *Microbiol*. 2009;4(3):323–39.
- 232 11. Mansueto P, Vitale G, Cascio A, Seidita A, Pepe I, Carroccio A, et al. New insight into
233 immunity and immunopathology of Rickettsial diseases. *Clin Dev Immunol*. 2012;
- 234 12. Pålsson C, Lu X, Ott M, Nilsson K. Characteristics of in vitro infection of human monocytes,
235 by Rickettsia helvetica. *Microbes Infect*. 2020;(xxxx).
- 236 13. Tizard I. Veterinary immunology. *Veterinary Immunology*. 2013. 519–521 p.

- 237 14. Fang R, Ismail N, Walker DH. Contribution of NK cells to the innate phase of host protection
238 against an intracellular bacterium targeting systemic endothelium. *Am J Pathol*.
239 2012;181(1):185–95.
- 240 15. Guo Y, Patil NK, Luan L, Bohannon JK, Sherwood ER. The biology of natural killer cells
241 during sepsis. *Immunology*. 2017;153(2):190–202.
- 242 16. Billings AN, Feng HM, Olano JP, Walker DH. Rickettsial infection in murine models
243 activates an early anti-rickettsial effect mediated by NK cells and associated with production
244 of gamma interferon. *Am J Trop Med Hyg*. 2001;65(1):52–6.
- 245 17. La Manna MP, Torina A, Agnone A, Blanda V, Caracappa S, Alongi A, et al. Detection of
246 Natural Killer T Cells in Mice Infected with *Rickettsia conorii*. *Transbound Emerg Dis*.
247 2013;60(SUPPL.2):80–5.
- 248 18. Jensenius M, Ueland T, Fournier PE, Brosstad F, Stylianou E, Vene S, et al. Systemic
249 inflammatory responses in African tick-bite fever. *J Infect Dis* [Internet]. 2003 Apr 15 [cited
250 2021 Oct 9];187(8):1332–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/12696016/>
- 251 19. Rauch J, Eisermann P, Noack B, Mehlhoop U, Muntau B, Schäfer J, et al. Typhus Group
252 Rickettsiosis, Germany, 2010–2017. *Emerg Infect Dis* [Internet]. 2018 Jul 1 [cited 2021 Oct
253 9];24(7):1213. Available from: <https://pubmed.ncbi.nlm.nih.gov/30638764/>
- 254 20. Sahni SK, Rydkina E. Host-cell interactions with pathogenic *Rickettsia* species. *Future*
255 *Microbiol*. 2009;4(3):323–39.
- 256 21. Tappe D, Booken N, Boer-Auer A, Rauch J, Schmiedel S, Reich K. Histology and serum
257 cytokine responses in an imported rickettsia slovac infection, Germany. *Am J Trop Med Hyg*
258 [Internet]. 2018 [cited 2021 Oct 9];98(1):248–51. Available from:
259 <https://pubmed.ncbi.nlm.nih.gov/29141745/>
- 260 22. Vitale G, Mansueto S, Gambino G, Mocciaro C, Spinelli A, Rini GB, et al. The acute phase
261 response in Sicilian patients with boutonneuse fever admitted to hospitals in Palermo, 1992-
262 1997. *J Infect* [Internet]. 2001 [cited 2021 Oct 9];42(1):33–9. Available from:
263 <https://pubmed.ncbi.nlm.nih.gov/11243751/>
- 264 23. de Pablo R, Monserrat J, Torrijos C, Martín M, Prieto A, Alvarez-Mon M. The predictive role
265 of early activation of natural killer cells in septic shock [Internet]. Vol. 16, *Critical Care*. *Crit*
266 *Care*; 2012 [cited 2021 Oct 9]. Available from: <https://pubmed.ncbi.nlm.nih.gov/22405329/>
- 267 24. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, Darbon R, et al. Early assessment of
268 leukocyte alterations at diagnosis of septic shock. *Shock* [Internet]. 2010 Oct [cited 2021 Oct
269 9];34(4):358–63. Available from: <https://pubmed.ncbi.nlm.nih.gov/20220566/>
- 270 25. Holub M, Klučková Z, Helcl M, Přihodov J, Rokyta R, Beran O. Lymphocyte subset numbers
271 depend on the bacterial origin of sepsis. *Clin Microbiol Infect* [Internet]. 2003 Mar 1 [cited
272 2021 Oct 9];9(3):202–11. Available from: <https://pubmed.ncbi.nlm.nih.gov/12667252/>
- 273 26. Jost S, Quillay H, Reardon J, Peterson E, Simmons RP, Parry BA, et al. Changes in cytokine
274 levels and NK cell activation associated with influenza. *PLoS One* [Internet]. 2011 Sep 23

[cited 2021 Oct 9];6(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/21966414/>

27. Zheng Q, Zhu YY, Chen J, Ye YB, Li JY, Liu YR, et al. Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection. Clin Exp Immunol [Internet]. 2015 Jun 1 [cited 2021 Oct 9];180(3):499–508. Available from: <https://pubmed.ncbi.nlm.nih.gov/25639451/>
28. Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, et al. Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care [Internet]. 2006 Nov 27 [cited 2021 Oct 9];10(6). Available from: <https://pubmed.ncbi.nlm.nih.gov/17129388/>
29. Kang SJ, Jin HM, Cho YN, Kim SE, Kim UJ, Park KH, et al. Increased level and interferon- γ production of circulating natural killer cells in patients with scrub typhus. PLoS Negl Trop Dis [Internet]. 2017 Jul 27 [cited 2021 Oct 9];11(7). Available from: <https://pubmed.ncbi.nlm.nih.gov/28750012/>
30. Stojanovic A, Correia MP, Cerwenka A. The NKG2D/NKG2DL axis in the crosstalk between lymphoid and myeloid cells in health and disease [Internet]. Vol. 9, Frontiers in Immunology. Front Immunol; 2018 [cited 2021 Oct 9]. Available from: <https://pubmed.ncbi.nlm.nih.gov/29740438/>

10 Supplementary Material

Supplementary Figure 1. Gating strategy and identification of human NK cells. Whole blood was incubated with target cells for 15 minutes at 4°C, surface stained with fluorochrome-conjugated anti-CD3, anti-CD16, anti-CD56, anti-CD57, anti-NKG2A and anti-NKG2D mAbs. Profiles demonstrate the gating strategy [side scatter (SSC) vs. forward scatter (FCS) and CD56 vs. CD3] for identification of NK cells (CD3⁺CD56⁺), effector NK cells (CD16^{dim}CD56^{bright}), cells Cytotoxic NKs (CD16^{bright}CD56^{dim}), CD57-expressing NK cells (CD56⁺CD57⁺), NK cells expressing NKG2D (CD56⁺NKG2D⁺) and NK cells expressing NKG2A (CD56⁺NKG2A⁺) cell populations. Profiles also show CD56 versus CD57, NKG2A and NKG2D staining on CD3⁺CD56⁺ NK cells for one representative donor after incubation of whole blood sample with indicated target cells, analysis was carried out with FlowJo software.

11 Figure legends

Figure 1. Proinflammatory cytokine levels in sera from children with rickettsiosis during the acute phase. Four sera from children infected with *Rickettsia rickettsii* and eight sera from healthy children were analyzed in parallel by the bead-based human inflammatory cytokine kit assay. Data are expressed as mean $\pm$ SD. Statistical analyzes were performed with the test of Kruskal-Wallis and Dunn's subsequent multiple comparison test. Asterisks indicate differences statistically significant (* p < 0.05, ** p < 0.01).

Figure 2. Chemokine levels in sera from patients with acute rickettsiosis. Sera obtained from children infected with *Rickettsia rickettsii* and eight sera from healthy children were analyzed in parallel by the bead-based human chemokine kit assay. Data are expressed as mean $\pm$ SD. Statistical analyzes were performed with the test of Kruskal-Wallis and Dunn's subsequent multiple comparison test. Asterisks indicate differences statistically significant (* p < 0.05, ** p < 0.01).

315 **Figure 3. Levels of cytokines involved in Th1 / Th2 / Th17 responses in sera from children with**
 316 **rickettsiosis during the acute phase.** Sera obtained from children infected with *Rickettsia rickettsii*
 317 and eight sera from healthy children were analyzed in parallel by the bead-based human Th1 / Th2 /
 318 Th17 cytokine kit assay. Data are expressed as mean $\pm$ SD. Statistical analyzes were performed with
 319 the test of Kruskal-Wallis and Dunn's subsequent multiple comparison test. Asterisks indicate
 320 differences statistically significant (* $p < 0.05$, ** $p < 0.01$).

321 **Figure 4. Percentage of NK cells (CD3⁺CD56⁺), effector NK cells (CD16^{dim}CD56^{bright}), cells**
 322 **Cytotoxic NKs (CD16^{bright}CD56^{dim}), CD57-expressing NK cells (CD56⁺CD57⁺), NK cells**
 323 **expressing NKG2D (CD56⁺NKG2D⁺) and NK cells expressing NKG2A (CD56⁺NKG2A⁺) in**
 324 **blood obtained from children with rickettsiosis during the acute phase and healthy controls.** Two
 325 analyzes were performed on parallel in four sera from children with rickettsiosis. The first analysis
 326 upon admission to the hospital and a second analysis 3 days after treatment, and the second serum from
 327 healthy blood donor children. The data are expressed as mean $\pm$ SD. Statistical analyzes were
 328 performed with the Kruskal-Wallis test and the subsequent Dunn multiple comparison test. Asterisks
 329 indicate differences statistically significant ($p < 0.01$).

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Figure 1

Figure 2

Figure 3

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Figure 4

Supp Fig 1